IYH iShares U.S. Healthcare ETF
Company Analysis
Latest News
Eli Lilly acquires AtaiBeckley for $3.8B, targeting depression with psychedelic drugs
Eli Lilly agreed to acquire biopharmaceutical firm AtaiBeckley for up to $3.8 billion. The deal marks Lilly’s first major expansion into the psychedelic drug...
Eli Lilly buys AtaiBeckley for $3.8B, expanding into psychedelic depression treatments
Eli Lilly agreed to acquire clinical-stage AtaiBeckley for up to $3.8 billion. The transaction consists of a $2.8 billion upfront cash payment and up to $1...
HCA Healthcare Raises 2026 Outlook, Citing Strong Q2 Revenue Growth
HCA Healthcare reported preliminary second-quarter results that exceeded analyst expectations. The company anticipates Q2 revenue of approximately $20.23...
HCA Healthcare raises 2026 outlook, fueled by $20.23 billion Q2 revenue
HCA Healthcare reported preliminary second-quarter results that exceeded market expectations. The company projects Q2 revenue of approximately $20.23 billion,...
Novo Nordisk advances hemophilia drug denecimig, expanding rare disease portfolio
Novo Nordisk announced positive Phase 3 results for denecimig (Mim8), an investigational hemophilia A treatment. The company presented the FRONTIER4 long-term...
Sanofi wins FDA approval for wearable Sarclisa, cutting myeloma treatment time
The U.S. Food and Drug Administration (FDA) approved a subcutaneous version of Sanofi’s multiple myeloma drug, Sarclisa (isatuximab-irfc). This new formulation...
Ionis and AstraZeneca Fail Phase 3, Stalling Lucrative Eplontersen Expansion
Ionis Pharmaceuticals (Nasdaq: IONS) and AstraZeneca announced today that their Phase 3 CARDIO-TTRansform trial for eplontersen failed its primary endpoint....
Novo Nordisk tests semaglutide implant, countering Eli Lilly in obesity market
Novo Nordisk partnered with Vivani Medical to evaluate NPM-139, a miniature subdermal implant for semaglutide. This active ingredient currently powers the...
Novartis to acquire Myricx Bio for $1.5B, strengthening cancer therapy pipeline
Novartis signed a definitive agreement to acquire Myricx Bio for up to $1.5 billion. The UK-based preclinical oncology company will receive an upfront cash...
Novartis to Acquire Myricx Bio for $1.5B, Strengthening Cancer Drug Pipeline
Novartis entered an agreement to acquire UK-based biotechnology company Myricx Bio for up to $1.5 billion. The deal includes an initial $1.1 billion upfront...
Amgen Tavneos Data Retracted From NEJM, Citing FDA Integrity Probe
The New England Journal of Medicine retracted pivotal data for Amgen’s autoimmune drug, Tavneos. Two academic authors requested the retraction following an...
Moderna Surges 10% as FDA Panel Unanimously Backs mRNA Flu Vaccine
An FDA advisory committee voted 16-0 to recommend Moderna's mRNA-based influenza vaccine. This unanimous endorsement signals a high likelihood of full FDA...
CMS launches Medicare GLP-1 Bridge, capping Wegovy and Zepbound at $50
CMS officially launched the Medicare GLP-1 Bridge program on July 1, 2026. Eligible Medicare Part D beneficiaries can now access Wegovy and Zepbound for a...
AbbVie Wins FDA Approval for Pediatric Skyrizi, First IL-23 for Kids
The U.S. Food and Drug Administration (FDA) approved AbbVie's Skyrizi (risankizumab-rzaa) for children aged 6 and older. This approval covers pediatric...
Sandoz Challenges Eli Lilly With Generic Mounjaro and Zepbound Filings
The FDA accepted two applications from Swiss drugmaker Sandoz for generic versions of Eli Lilly’s tirzepatide medications, Mounjaro and Zepbound. These...
Merck KGaA Buys Bio-Techne for $11.3 Billion, Expanding Research Tools
Merck KGaA will acquire U.S. biotech firm Bio-Techne for $11.3 billion. The all-cash offer provides $73 per share to Bio-Techne investors. This price...
🟢 IYH is trading 3% up today on defensive rotation and healthcare M&A activity
IYH is trading 3% up today as investors rotate toward defensive, non-tech sectors following recent pressure in technology and AI-related names. • A volatile...
Merck KGaA Buys Bio-Techne for $11.3 Billion, Expanding High-Growth Life Sciences
Merck KGaA entered a definitive agreement to acquire Bio-Techne Corp. for $73 per share in cash. The transaction represents a total enterprise value of...
Merck Gains EU Approval for Keytruda-Padcev, Cutting Bladder Cancer Death Risk 50%
Merck received European Commission approval for KEYTRUDA in combination with the antibody-drug conjugate Padcev. The regimen treats adult patients with...
REGENXBIO Clears FDA Hurdle for NAVSUNLI™, No New Trials Needed
REGENXBIO reached an agreement with the FDA on a path to resubmit its Biologics License Application (BLA) for NAVSUNLI™. This one-time gene therapy targets...